<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02836925</url>
  </required_header>
  <id_info>
    <org_study_id>FIL_BArT</org_study_id>
    <nct_id>NCT02836925</nct_id>
  </id_info>
  <brief_title>Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection</brief_title>
  <official_title>A Multicenter Study to Evaluate the Anti-viral Activity of an Interferon-free Treatment With Ledipasvir/Sofosbuvir (G1 and G4) and Sofosbuvir/Velpatasvir (G2 and G3) for Patients With Hepatitis C Virus-associated Indolent B-cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized, a single arm, phase II multicentre study of sofosbuvir plus
      ledipasvir (genotype 1 and 4) or sofosbuvir plus velpatasvir (genotype 2 and 3) for patients
      with hepatitis C virus-associated indolent B-cell lymphomas (HCV-RNA positive).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study includes an antiviral treatment with interferon-free regimen followed by lymphoma
      restaging; following the end of antiviral treatment patients will be evaluated for sustained
      virological response and safety parameters every 3 months for 1 year and then every 6 months
      for 2 years. ORR and vital status will be also evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SVR12</measure>
    <time_frame>12 weeks from the end of the treatment</time_frame>
    <description>Sustained virologic response (SVR12) defined as undetectability of HCV-RNA 12 weeks after completion of antiviral therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>12 weeks from the end of treatment</time_frame>
    <description>Overall response rate (ORR) of lymphoma: CR is defined by the complete disappearance of all detectable sites and symptoms; PR is defined as a more than 50% reduction. Responses different from CR/PR are defined as stable disease (SD); progressive disease (PD) is considered an increase in size of more than 50% of previously documented disease or the appearance of new lesions. Lymphoma response will be assessed 12 weeks after the end of antiviral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>36 months</time_frame>
    <description>Progression‐free survival (PFS) defined as the time between enrolment and progression or relapse or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFS</measure>
    <time_frame>36 months</time_frame>
    <description>Event‐free survival (EFS) defined as time between enrolment and failure of treatment or death as a result of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>36 months</time_frame>
    <description>Overall survival (OS) defined as the time between enrolment and death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR for lymphoma</measure>
    <time_frame>12 weeks from the end of treatment</time_frame>
    <description>ORR for lymphoma according to Matutes criteria (Matutes et al, Leukemia 2008) only in patients with splenic-marginal zone lymphoma (SMZL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapid virological response</measure>
    <time_frame>4 weeks</time_frame>
    <description>rapid virologic response (RVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extended rapid virological response</measure>
    <time_frame>4 weeks</time_frame>
    <description>extended RVR (eRVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early virological response</measure>
    <time_frame>4 weeks</time_frame>
    <description>early virologic response (EVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity - Incidence of Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>toxicity will be classified according to definitions of Common Terminology Criteria for Adverse Event version 4.03 (CTCAE). It will be determined by the incidence of severe, life‐threatening (CTCAE grade 3, 4 and 5) and/or serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Indolent B-cell Lymphoma</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Ledipasvir+Sofosbuvir,Sofosbuvir+Velpatasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study includes an antiviral treatment with interferon-free regimen followed by lymphoma restaging; following the end of antiviral treatment patients will be evaluated for sustained virological response and safety parameters every 3 months for 1 year and then every 6 months for 2 years. ORR and vital status will be also evaluated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ledipasvir+Sofosbuvir</intervention_name>
    <description>Patients with genotype 1 or genotype 4 Ledipasvir 90 mg + Sofosbuvir 400 mg
12 weeks in previously untreated infected patients
24 weeks for previously treated patients with uncertain subsequent retreatment options</description>
    <arm_group_label>Ledipasvir+Sofosbuvir,Sofosbuvir+Velpatasvir</arm_group_label>
    <other_name>Harvoni</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir+Velpatasvir</intervention_name>
    <description>Patients with genotype 2 or genotype 3 Sofosbuvir 400 mg + Velpatasvir 100 mg
· 12 weeks of treatment</description>
    <arm_group_label>Ledipasvir+Sofosbuvir,Sofosbuvir+Velpatasvir</arm_group_label>
    <other_name>Epclusa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;18 years

          2. Indolent B cell lymphoma including: marginal zone lymphoma (nodal, extranodal, splenic
             and disseminated), lymphoplasmacytic lymphoma, small lymphocytic lymphoma, follicular
             lymphoma grade 1 and 2, CD5‐negative B‐cell lymphoma NOS

          3. HCV‐RNA positivity

          4. Assessable HCV genotype

          5. No previous therapy for the lymphoma

          6. Measurable disease after diagnostic biopsy (longest axis ≥1.5 cm for nodal and ≥1 cm
             for extranodal lesions) and/or evaluable disease (quantifiable BM infiltrate and ≥5 x
             109/l clonal B-cell in peripheral blood in case of exclusive BM/leukemic disease in
             CD5-negative Bcell lymphoma NOS)

          7. No need of immediate lymphoma treatment defined as absence of all the following
             criteria: systemic symptoms, bulky nodal or extranodal mass (&gt;7 cm), symptomatic
             splenomegaly, progressive leukemic phase, serous effusions

          8. Performance status &lt;2 according to ECOG scale

          9. Adequate hematological counts: ANC &gt;1 x 109/L, hemoglobin &gt;9 g/dl (transfusion
             independent), platelet count &gt; 50 x 109/L (transfusion independent)

         10. No central nervous system (CNS) disease (meningeal and/or brain involvement by
             lymphoma)

         11. Adequate kidney function (creatinine clearance ≥ 45 ml/min)

         12. Cardiac ejection fraction ≥45% (echocardiography or MUGA scan)

         13. Normal lung function

         14. Non peripheral neuropathy or active neurological non neoplastic disease of CNS

         15. Non major surgical intervention prior 3 months to enrolment if not due to lymphoma
             and/or no other disease life‐threatening that can compromise chemotherapy treatment

         16. Disease free of prior malignancies other than lymphoma for &gt;3 years with exception of
             currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in
             situ of the cervix or breast

         17. Life expectancy &gt; 6 months

         18. No psychiatric illness that precludes understanding concepts of the trial or signing
             informed consent

         19. Written informed consent

         20. Women must be:

               -  postmenopausal for at least 1 year (must not have had a natural menses for at
                  least 12 months)

               -  surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal
                  ligation, or otherwise be incapable of pregnancy),

               -  completely abstinent (at the discretion of the investigator/per local
                  regulations) (periodic abstinence from intercourse is not permitted) or

               -  if sexually active, be practicing a highly effective method of birth control (eg,
                  prescription oral contraceptives, contraceptive injections, contraceptive patch,
                  intrauterine device, double‐barrier method (eg: condoms, diaphragm, or cervical
                  cap, with spermicidal foam, cream, or gel, male partner sterilization) as local
                  regulations permit, before entry, and must agree to continue to use the same
                  method of contraception throughout the study. They must also be prepared to
                  continue birth control measures for at least 6 months after terminating
                  treatment.

         21. Women of childbearing potential must have a negative serum or urine beta‐human
             chorionic gonadotropin (beta-hCG) pregnancy test at screening

         22. Men must agree to use an acceptable method of contraception (for themselves or female
             partners as listed above) for the duration of the study. Men must agree to use a
             double barrier method of birth control and to not donate sperm during the study and
             for 1 month after receiving the last dose of study drug if not taking ribavirin of for
             6 months after receiving the last dose of study drug if taking ribavirin.

        Exclusion Criteria:

          1. Diagnosis of lymphoblastic lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma,
             mantle cell lymphoma, follicular lymphoma grade 3, primary mediastinal B-cell lymphoma

          2. Previous anti-HCV treatment with sustained virological response

          3. Diagnosis of cirrhosis (histological or Stiffness &gt;12 KpA)

          4. CNS disease (meningeal and/or brain involvement by lymphoma)

          5. History of clinically relevant liver or renal insufficiency; significant cardiac,
             vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic,
             hematologic, psychiatric, or metabolic disturbances

          6. Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable
             dose for at least 3 months before first dose of study drug)

          7. Concomitant therapy with amiodarone

          8. Uncontrolled or severe cardiovascular disease including myocardial infarction within
             six months of enrollment, New York Heart Association (NYHA) Class III or IV heart
             failure, uncontrolled angina,

          9. Cardiac ejection fraction &lt;45% (MUGA scan or echocardiography).

         10. Creatinine clearance &lt;45 ml/min

         11. Presence of major neurological disorders

         12. HIV positivity, HBV positivity (HbsAg+ or HBV-DNA+) with the exception of HBcAb+,
             HbsAg-, HBsAb+/- patients with HBV-DNA negativity

         13. Ongoing systemic bacterial, fungal or viral infections at the time of initiation of
             study treatment (defined as requiring therapeutic dosing of an antimicrobial,
             antifungal or antiviral agent)

         14. Major surgical intervention prior 3 months to enrollment if not due to lymphoma and/or
             other

         15. Prior malignancies other than lymphoma in the last 3 years with exception of currently
             treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the
             cervix or breast

         16. Life expectancy &lt;6 months

         17. Any other coexisting medical or psychological condition that would preclude
             participation in the study or compromise ability to give informed consent.

         18. If female, the patient is pregnant or breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Arcaini</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico San Matteo Pavia Fondazione IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uffici Studi FIL Fondazione Italiana Linfomi</last_name>
    <phone>0039</phone>
    <phone_ext>0131206288</phone_ext>
    <email>segreteria@filinf.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>A.O. Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Motta, MD</last_name>
      <phone>+39 0303996269</phone>
      <email>marina.motta@spedalicivili.brescia.it</email>
    </contact>
    <investigator>
      <last_name>Marina Motta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Baldini, MD</last_name>
      <phone>0039 02 55033334</phone>
      <email>luca.baldini@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Luca Baldini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irccs Centro Di Riferimento Oncologico (Cro)</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33801</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Spina</last_name>
      <email>mspina@cro.it</email>
    </contact>
    <investigator>
      <last_name>Michele Spina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <state>VI</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Visco, MD</last_name>
      <phone>+39 0444-753626/3518</phone>
      <email>carlovisco@hotmail.com;silvia.finotto@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Carlo Visco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico G.B. Rossi (Borgo Roma) Di Verona</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dino Veneri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Careggi Di Firenze</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luigi Rigacci</last_name>
    </contact>
    <contact_backup>
      <email>luigi.rigacci@unifi.it</email>
    </contact_backup>
    <investigator>
      <last_name>Luigi Rigacci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sc Ematologia Ao Niguarda Ca' Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra Tedeschi</last_name>
      <email>alessandra.tedeschi@ospedaleniguarda.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anna Dodero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrés Ferreris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonello Pinto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia AO di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Piazza</last_name>
      <email>francesco.piazza@unipd.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Piazza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico P.Giaccone</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Emilio Iannitto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>fre@ao.pr.it</email>
    </contact>
    <investigator>
      <last_name>Francesca Re, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Arcaini, M.D.</last_name>
      <phone>00390382503595</phone>
      <email>luca.arcaini@unipv.it</email>
    </contact>
    <investigator>
      <last_name>Luca Arcaini, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia - Policlinico Umberto I Università Sapienza</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Pulsoni</last_name>
      <email>pulsoni@bce.uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Pulsoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia Medica ed Ematologia, Istituto Humanitas</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armando Santoro, MD</last_name>
    </contact>
    <investigator>
      <last_name>Armando Santoro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorella Orsucci, MD</last_name>
      <email>lorsucci@cittadellasalute.to.it</email>
    </contact>
    <investigator>
      <last_name>Lorella Orsucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria S. Maria Della Misericordia Di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francesco Zaja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michele Merli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2016</study_first_submitted>
  <study_first_submitted_qc>July 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <keyword>NHL</keyword>
  <keyword>Indolent B-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

